Lipopolysaccharide-induced depressive-like, anxiogenic-like and hyperalgesic behavior is attenuated by acute administration of α-(phenylselanyl) acetophenone in mice.
Acetophenones
/ pharmacokinetics
Animals
Anti-Anxiety Agents
/ pharmacology
Antidepressive Agents
/ pharmacology
Anxiety
/ chemically induced
Behavior, Animal
/ drug effects
Computer Simulation
Cyclooxygenase 2
/ metabolism
Depression
/ chemically induced
Exploratory Behavior
/ drug effects
Hyperalgesia
/ chemically induced
Lipopolysaccharides
/ pharmacology
Mice
Motor Activity
/ drug effects
Organoselenium Compounds
/ pharmacokinetics
Transcription Factor RelA
/ metabolism
p38 Mitogen-Activated Protein Kinases
/ metabolism
Anxiety
Depression
Pain
Selenium
Synaptic signaling
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
received:
09
08
2018
revised:
25
10
2018
accepted:
19
11
2018
pubmed:
24
11
2018
medline:
24
1
2020
entrez:
24
11
2018
Statut:
ppublish
Résumé
The lipopolysaccharide (LPS) is an endotoxin derived from gram-negative bacteria, which induces inflammation. The aims of this study were to evaluate the possible α-(phenylselanyl) acetophenone (PSAP) activity in reducing comorbid hyperalgesia, depressive-like and anxiogenic-like symptoms induced by LPS in mice. In additional, investigated physical chemical properties of PSAP through in silico analysis by ADMET predictor software. The LPS (100 μg/kg, intraperitoneally) or saline were administered and after 4 h the treatment with PSAP (0.001-10 mg/kg, intragastric route [i.g.]) or FLX (10 mg/kg, i.g.) was performed, and after 30 min, the behavioral tests were carried out. LPS reduced the latency time for the first episode of immobility and increased the immobility time in the FST as well as decreased the grooming time in the splash test. PSAP reversed these alterations demonstrating an antidepressive-like effect. LPS also enhances the anxiogenic behavior in the elevated plus maze test (EPM). PSAP reversed these parameters, showing anxiolytic-like effect. LPS also decreased the latency time (s) on the hot plate and the treatment with PSAP at all doses significantly reversed the hyperalgesic effect of LPS. LPS increased the activation of p38MAPK and p-p65NF-κB pathways as well as the COX-2 levels in the cerebral cortex, which are indicative of an inflammatory response. Besides, it also reduced the levels of mBDNF, involved in neuroplasticity. Treatment with PSAP restored all these neurochemical alterations induced by LPS. The results demonstrated that PSAP presents antidepressive-like, anxiolytic-like and anti-hyperalgesic effects related to reduction in neuroinflammation.
Identifiants
pubmed: 30468797
pii: S0028-3908(18)30498-2
doi: 10.1016/j.neuropharm.2018.11.028
pii:
doi:
Substances chimiques
Acetophenones
0
Anti-Anxiety Agents
0
Antidepressive Agents
0
Lipopolysaccharides
0
Organoselenium Compounds
0
Rela protein, mouse
0
Transcription Factor RelA
0
alpha-(phenylselanyl)acetophenone
0
Cyclooxygenase 2
EC 1.14.99.1
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-137Informations de copyright
Copyright © 2018. Published by Elsevier Ltd.